Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05734495 · ClinicalTrials.gov registry record · Phase 2
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
A Phase 2 study of Waldenstrom Macroglobulinemia, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 2
- Study locations
NCT05734495: Recruiting Phase 2 study of Waldenstrom Macroglobulinemia, sponsored by Dana-Farber Cancer Institute.
NCT05734495 is a Phase 2 study of Waldenstrom Macroglobulinemia that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 42 participants, below the 472-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05734495, a Phase 2 study of Waldenstrom Macroglobulinemia, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is being done to examine the safety and effectiveness of pirtobrutinib combined with venetoclax as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The names of the study drugs involved in this study are: * Pirtobrutinib (a Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor) * Venetoclax (a BCL2 inhibitor)
Primary Outcome
VGPR or better response rate is defined as proportion of participants experienced VGPR or complete response (CR) based on modified 6th International Workshop on WM \[IWWM\] criteria (NCCN 2014).
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Pirtobrutinib
Study Locations (2)
Massachusetts
- Beth Israel Deaconness Medical - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-05-02 |
| Est. Completion | 2033-01-25 |
| Phase | Phase 2 |
What NCT05734495 shows while recruiting
NCT05734495 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 472-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Waldenstrom Macroglobulinemia appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT05734495 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05734495 about?
NCT05734495 is a clinical study titled "Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia". This study is being done to examine the safety and effectiveness of pirtobrutinib combined with venetoclax as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The names of the study drugs involved in this study are: * Pirtobrutinib (a Noncovalent Bruton Tyrosine Kinas...
What is the current status of trial NCT05734495?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2023-05-02. Estimated completion is 2033-01-25.
What conditions does trial NCT05734495 study?
This clinical trial studies the following conditions: Waldenstrom Macroglobulinemia.
What interventions are being tested in trial NCT05734495?
The interventions under investigation include: Venetoclax (DRUG), Pirtobrutinib (DRUG).
Who is sponsoring clinical trial NCT05734495?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05734495 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Waldenstrom Macroglobulinemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05734495's enrollment target sits among peer trials
42 23rd of 34 higher than 12 of 34 other Waldenstrom Macroglobulinemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Waldenstrom Macroglobulinemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
RECRUITING · Phase 2
-
Epcoritamab in Previously Treated WM
RECRUITING · Phase 2
-
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
RECRUITING · Phase 2
-
Loncastuximab Tesirine in WM
RECRUITING · Phase 2
-
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
RECRUITING · Phase 2
-
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI